Eli Lilly’s ongoing technical evaluation of Peptron’s SmartDepot microsphere platform for long-acting peptide formulations, including GLP-1 candidates, has not progressed to a commercial licensing agreement despite the October 7, 2026 evaluation deadline. Joint research expanded in July 2026 to cover next-generation GLP-1 agents and CNS indications such as Alzheimer’s, with initial validation reportedly complete, yet Lilly maintains flexibility to terminate the non-binding deal with 30 days’ notice and continues parallel work with other sustained-release technologies like Camurus’ FluidCrystal. Additional in-vivo studies and Peptron’s independent advancement of its own once-monthly semaglutide candidate further indicate the partnership remains in feasibility assessment rather than final commercialization talks. Traders price the 87.5% “No” outcome on the absence of any licensing announcement near the tight deadline.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日13% 確率
$11,314 Vol.
$11,314 Vol.
2026/10/06
13% 確率
$11,314 Vol.
$11,314 Vol.
2026/10/06
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technical evaluation of Peptron’s SmartDepot microsphere platform for long-acting peptide formulations, including GLP-1 candidates, has not progressed to a commercial licensing agreement despite the October 7, 2026 evaluation deadline. Joint research expanded in July 2026 to cover next-generation GLP-1 agents and CNS indications such as Alzheimer’s, with initial validation reportedly complete, yet Lilly maintains flexibility to terminate the non-binding deal with 30 days’ notice and continues parallel work with other sustained-release technologies like Camurus’ FluidCrystal. Additional in-vivo studies and Peptron’s independent advancement of its own once-monthly semaglutide candidate further indicate the partnership remains in feasibility assessment rather than final commercialization talks. Traders price the 87.5% “No” outcome on the absence of any licensing announcement near the tight deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
マーケット開始日： May 5, 2026, 8:02 PM ET
音量
$11,314終了日
2026/10/07マーケット開始日
May 5, 2026, 8:02 PM ETリゾルバー
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technical evaluation of Peptron’s SmartDepot microsphere platform for long-acting peptide formulations, including GLP-1 candidates, has not progressed to a commercial licensing agreement despite the October 7, 2026 evaluation deadline. Joint research expanded in July 2026 to cover next-generation GLP-1 agents and CNS indications such as Alzheimer’s, with initial validation reportedly complete, yet Lilly maintains flexibility to terminate the non-binding deal with 30 days’ notice and continues parallel work with other sustained-release technologies like Camurus’ FluidCrystal. Additional in-vivo studies and Peptron’s independent advancement of its own once-monthly semaglutide candidate further indicate the partnership remains in feasibility assessment rather than final commercialization talks. Traders price the 87.5% “No” outcome on the absence of any licensing announcement near the tight deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$11,314終了日
2026/10/07マーケット開始日
May 5, 2026, 8:02 PM ETリゾルバー
0x65070BE91...Eli Lilly’s ongoing technical evaluation of Peptron’s SmartDepot microsphere platform for long-acting peptide formulations, including GLP-1 candidates, has not progressed to a commercial licensing agreement despite the October 7, 2026 evaluation deadline. Joint research expanded in July 2026 to cover next-generation GLP-1 agents and CNS indications such as Alzheimer’s, with initial validation reportedly complete, yet Lilly maintains flexibility to terminate the non-binding deal with 30 days’ notice and continues parallel work with other sustained-release technologies like Camurus’ FluidCrystal. Additional in-vivo studies and Peptron’s independent advancement of its own once-monthly semaglutide candidate further indicate the partnership remains in feasibility assessment rather than final commercialization talks. Traders price the 87.5% “No” outcome on the absence of any licensing announcement near the tight deadline.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問